- Home
- MRNA vs JEF Comparison
MRNA vs JEF Comparison
Compare MRNA & JEF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRNA | JEF |
|---|---|---|
| Founded | 2010 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 10.5B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | MRNA | JEF |
|---|---|---|
| Price | $32.80 | $63.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | $33.25 | ★ $76.00 |
| AVG Volume (30 Days) | ★ 10.6M | 1.6M |
| Earning Date | 02-13-2026 | 01-07-2026 |
| Dividend Yield | N/A | ★ 2.52% |
| EPS Growth | N/A | ★ 25.06 |
| EPS | N/A | ★ 2.92 |
| Revenue | $2,232,000,000.00 | ★ $7,231,501,000.00 |
| Revenue This Year | N/A | $5.44 |
| Revenue Next Year | $0.77 | $11.00 |
| P/E Ratio | ★ N/A | $21.75 |
| Revenue Growth | N/A | ★ 15.68 |
| 52 Week Low | $22.28 | $39.28 |
| 52 Week High | $48.92 | $82.68 |
Technical Indicators
Market Signals| Indicator | MRNA | JEF |
|---|---|---|
| Relative Strength Index (RSI) | 66.19 | 69.00 |
| Support Level | $32.14 | $61.50 |
| Resistance Level | $35.90 | $64.54 |
| Average True Range (ATR) | 1.65 | 1.83 |
| MACD | 0.49 | 0.25 |
| Stochastic Oscillator | 70.53 | 88.74 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About JEF Jefferies Financial Group Inc.
Jefferies is a full-service investment banking and capital markets firm that was founded in 1962. After nearly 30 years of focusing on institutional trading services, it entered the investment banking industry in the early 1990s, which ultimately grew into the core business. In 2013, Jefferies merged with Leucadia, a manufacturing-focused holding company. Since merging, Jefferies became the bedrock of the business as the bulk of the legacy portfolio was sold off and the parent company was renamed to match the subsidiary. Within the investment banking landscape, Jefferies predominately serves the North American middle market and has captured considerable market share over the past decade.